Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SV102
- Development stage
- Preclinical
- Lead developer
- Syncromune
- Modality
- Vaccines & Immunotherapeutics
01
Overview
SV102 is a live-attenuated vaccine candidate being developed by Sysvax for the prevention of brucellosis. Brucellosis is a zoonotic infection caused by bacteria of the genus *Brucella*, which can lead to chronic health issues in humans, including undulant fever, arthritis, and endocarditis. The vaccine is designed to induce a robust and lasting immune response by presenting the immune system with a weakened version of the pathogen, thereby stimulating both humoral and cellular immunity without causing the disease. SV102 is currently in the preclinical stage of development and represents a potential advancement in the prevention of this widespread zoonotic threat.
- Other names
- SV102-SysvaxSV-102-SysvaxSV 102-Sysvax
Beyond the preview
Go deeper on SV102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SV102.